This is a preview of subscription content, log in via an institution to check access.
Notes
disease-modifying antirheumatic drugs
References
1. Farih S, et al. Direct Cost of Biologics in Rheumatoid Arthritis Patients in a Developing Country: Results for the Moroccan Rbsmr Registry. 22nd Annual Congress of the European League Against Rheumatism : abstr. AB0811, 2 Jun 2021. Available from: URL: http://scientific.sparx-ip.net/archiveeular/index.cfm?view=2&c=a&item=2021AB0811
2. Farih S, et al. Do Social Factors Impact on Biologics Costs in Rheumatoid Arthritis? Results from the Moroccan Rbsmr Registry. 22nd Annual Congress of the European League Against Rheumatism : abstr. POS1417, 2 Jun 2021. Available from: URL: http://scientific.sparx-ip.net/archiveeular/index.cfm?view=2&c=a&item=2021POS1417
3. Bahloul S, et al. One-Year Direct Costs of Biological Therapy in Ankylosing Spondylitis and its Predictive Factors: Data from the Moroccan Rbsmr Registry. 22nd Annual Congress of the European League Against Rheumatism : abstr. AB0486, 2 Jun 2021. Available from: URL: http://scientific.sparx-ip.net/archiveeular/index.cfm?c=a&view=2&item=2021AB0486
Rights and permissions
About this article
Cite this article
Direct costs of biologicals for RA and SpA in Morocco. PharmacoEcon Outcomes News 882, 9 (2021). https://doi.org/10.1007/s40274-021-7843-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-7843-4